Interstitial lung diseases (ILDs) are a group of rare and complex disorders characterized by immune involvement and/or fibrosis of the lungs. Encompassing over 200 distinct conditions, certain forms of ILDs are associated with a median survival of only 3 to 5 years after diagnosis, underscoring the urgent need for new therapeutic solutions.

In response to this unmet medical need, A.D.A. targets disease progression at multiple stages, from early immune modulation to fibrosis control, redefining how these complex diseases are treated. By advancing inhaled therapeutic solutions, treatments are delivered directly to the lungs, improving patient adherence while reducing systemic exposure and minimizing side effects.

Through this vision, A.D.A. aims to enable more effective, patient-centric therapies and set a new standard in respiratory care.